{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:07Z","timestamp":1793640727043,"version":"4.5.1"},"reference-count":23,"publisher":null,"issue":"6","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:underline>Purpose:<\/jats:underline>\n                    to assess drug therapy and achievement of target parameters of treatment in patients with ischemic heart disease (IHD) during 3\u20135 years of follow-up a\ufb05er coronary bypass surgery.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>Materials and methods<\/jats:underline>\n                    . From the initial sample of the coronary bypass surgery registry (n=680) we selected for this study 111 men (mean age 61 [55; 65] years) hospitalized in 2011 with clinical picture of IHD for coronary artery bypass gra\ufb05ing (CABG).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>Results.<\/jats:underline>\n                    Mean duration of follow-up was 4.2 years. Mortality was 11.7 % (n=13), 11 deaths were cardiovascular, 2 \u2013 from unknown causes. End points de\ufb01ned as repeat hospitalizations and IHD progression were registered in 18 of 98 patients (18.4 %). Only in 25 % of patients during 3\u20135 years of observation a\ufb05er CABG there were no clinical signs of angina. Five patients (5.1 %) developed new type 2 diabetes. Drug therapy: 80 patients (81.6 %) received acetylsalicylic acid, 60 (61.2 %) \u2013 angiotensin converting enzyme inhibitors, 80 (81.6 %) \u2013 \u03b2-adrenoblockers. Eighty-one men (82.6 %) received statins, but only 20 of 98 re-examined patients (20.4 %) took high doses. Target levels of low density lipoprotein cholesterol\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>Conclusion.<\/jats:underline>\n                    Data of clinical practice illustrate insu\ufb03cient quality of basic and antianginal therapy in patients with IHD a\ufb05er CABG. Indicators of control of angina, heart rate, achievement of target levels of parameters of lipid metabolism remain unsatisfactory.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2019.6.n536","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T03:36:27Z","timestamp":1561606587000},"page":"12-17","source":"Crossref","is-referenced-by-count":1,"title":["The Pathways to Increase the Efficacy of Drug Therapy in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting"],"prefix":"10.68900","volume":"59","author":[{"given":"O. L.","family":"Barbarash","sequence":"first","affiliation":[{"name":"Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. V.","family":"Kashtalap","sequence":"additional","affiliation":[{"name":"Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Zykov","sequence":"additional","affiliation":[{"name":"Research Institute for Complex Issues of Cardiovascular Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. N.","family":"Hryachkova","sequence":"additional","affiliation":[{"name":"Research Institute for Complex Issues of Cardiovascular Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A.","family":"Shibanova","sequence":"additional","affiliation":[{"name":"Research Institute for Complex Issues of Cardiovascular Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2019,6,27]]},"reference":[{"key":"ref1","unstructured":"Bokeria L. A. Modern tendencies in the development of cardiovascular surgery. Russian Journal of Thoracic and Cardiovascular Surgery. 2013;1:45\u201351. [Russian]"},{"key":"ref2","unstructured":"Bokeria L. A., Keren M. A., Enokyan L. G., Sigaev I. Yu., Merzlyakov V. Yu., Kazaryan A. V. et al. Long-term results of coronary artery bypass grafting in elderly and geriatric patients with ischemic heart disease. Russian Journal of Surgery. 2012;2:15\u201321. [Russian]"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Bokeria L. A., Aronov D. M. Russian clinical guidelines Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. CardioSomatics. 2016;7(3\u20134):5\u201371. [Russian]","DOI":"10.26442\/CS45210"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mohr FW, Morice M-C, Kappetein AP, Feldman TE, St\u00e5hle E, Colombo A et al. Coronary artery bypass graft surgery versus percu- taneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. The Lancet. 2013;381(9867):629\u201338. DOI: 10.1016\/S0140-6736(13)60141-5","DOI":"10.1016\/S0140-6736(13)60141-5"},{"key":"ref5","unstructured":"Sedykh D. Yu., Gorbunova E. V., Zykov M. V., Kashtalap V. V., Barbarash O. L. Factors associated with the risk of death and hospitalization in recurrent myocardial infarction. Creative Cardiology. 2017;11(2):98\u2013108. [Russian]"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Barbarash O. L., Karetnikova V. N., Kashtalap V. V. The patient after myocardial infarction: how to reduce a risk of recurrent ischemic event? CardioSomatics. 2015;6(2):12\u20139. [Russian]","DOI":"10.26442\/CS45109"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Kashtalap V. V., Khryachkova O. N., Barbarash O. L. \u201cNew\u201d patho- logical continuum: a hypogonadism, an osteoporosis and the cal- cinating atherosclerosis. General factors of formation and progression. Atherosclerosis. 2016;12(4):68\u201378. [Russian]","DOI":"10.15275\/kreatkard.2016.04.06"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Barbarash OL, Lebedeva NB, Kokov AN, Novitskaya AA, Hryachkova ON, Voronkina AV et al. Decreased Cathepsin K Plasma Level may Reflect an Association of Osteopoenia\/ Osteoporosis with Coronary Atherosclerosis and Coronary Artery Calcification in Male Patients with Stable Angina. Heart, Lung and Circulation. 2016;25(7):691\u20137. DOI: 10.1016\/j.hlc.2016.02.002","DOI":"10.1016\/j.hlc.2016.02.002"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Steg PG, Greenlaw N, Tendera M, Tardif J-C, Ferrari R, Al-Zaibag M et al. Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease: Data From the International Observational CLARIFY Registry. JAMA Internal Medicine. 2014;174(10):1651\u20139. DOI: 10.1001\/jamainternmed.2014.3773","DOI":"10.1001\/jamainternmed.2014.3773"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mozaffarian D, Bryson CL, Spertus JA, McDonell MB, Fihn SD. Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. American Heart Journal. 2003;146(6):1015\u201322. DOI: 10.1016\/S0002-8703(03)00436-8","DOI":"10.1016\/S0002-8703(03)00436-8"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Glezer M. G. Effect of treatment with Ivabradine on quality of life of patients with ischemic heart disease: results of the LINCOR program. Kardiologiia. 2015;55(2):4\u20139. [Russian]","DOI":"10.18565\/cardio.2015.2.4-9"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. The Lancet. 2008;372(9641):817\u201321. DOI: 10.1016\/S0140-6736(08)61171-X","DOI":"10.1016\/S0140-6736(08)61171-X"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Dyakov I. N., Glezer M. G. Clinical and economic efficacy of ivabradine in patients suffered myocardial infarction. Kardiologiia. 2015;55(3):49\u201355. [Russian","DOI":"10.18565\/cardio.2015.3.49-55"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Steg PG, Greenlaw N, Tardif J-C, Tendera M, Ford I, K\u00e4\u00e4b S et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. European Heart Journal. 2012;33(22):2831\u201340. DOI: 10.1093\/eurheartj\/ehs289","DOI":"10.1093\/eurheartj\/ehs289"},{"key":"ref15","unstructured":"Shalnova S. A., Oganov R. G. Five year dynamics of main clinical symptoms in patients with ischemicheart disease in Russiain comparison with other coutries (the CLARIFY Registry). Kardiologiia. 2017;57(1):17\u201322. [Russian]. DOI: 10.18565\/cardio.2017.1.17-22"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"De Bacquer D, De Smedt D, Kotseva K, Jennings C, Wood D, Ryd\u00e9n L et al. Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. European Journal of Epidemiology. 2019;34(3):247\u201358. DOI: 10.1007\/s10654-018-0454-0","DOI":"10.1007\/s10654-018-0454-0"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zarifis J, Grammatikou V, Kallistratos M, Katsivas A. Antianginal Effi cy of Ivabradine in Patients With History of Coronary Revascularization. Angiology. 2017;68(1):10\u20138. DOI: 10.1177\/0003319716630499","DOI":"10.1177\/0003319716630499"},{"key":"ref18","unstructured":"Karpov Yu. A., Glezer M. G., Vasyuk Yu. A., Saygitov R. T., Shkolnik E. L. Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results. Cardiovascular therapy and Prevention. 2011;10(8):83\u20139. [Russian]"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Dillinger J-G, Maher V, Vitale C, Henry P, Logeart D, Manzo Silberman S et al. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. Hypertension. 2015;66(6):1138\u201344. DOI: 10.1161\/HYPERTENSIONAHA.115.06091","DOI":"10.1161\/HYPERTENSIONAHA.115.06091"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Maranta F, Tondi L, Agricola E, Margonato A, Rimoldi O, Camici PG. Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia. Basic Research in Cardiology. 2015;110(6):55. DOI: 10.1007\/s00395-015-0511-8","DOI":"10.1007\/s00395-015-0511-8"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Bansilal S, Castellano JM, Garrido E, Wei HG, Freeman A, Spettell C et al. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. Journal of the American College of Cardiology. 2016;68(8):789\u2013801. DOI: 10.1016\/j.jacc.2016.06.005","DOI":"10.1016\/j.jacc.2016.06.005"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Levy AE, Huang C, Huang A, Michael Ho P. Recent Approaches to Improve Medication Adherence in Patients with Coronary Heart Disease: Progress Towards a Learning Healthcare System. Current Atherosclerosis Reports. 2018;20(1):5. DOI: 10.1007\/s11883-018-0707-0","DOI":"10.1007\/s11883-018-0707-0"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Divchev D, St\u00f6ckl G. Treatment of Stable Angina with a New Fixed- Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice. Cardiology and Therapy. 2017;6(2):239\u201349. DOI: 10.1007\/s40119-017-0099-1","DOI":"10.1007\/s40119-017-0099-1"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/717\/441","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:17:21Z","timestamp":1793639841000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,27]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2019.6.n536","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,27]]}}}